Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lenalidomide inhibits the malignant clone and up-regulates the <i>SPARC</i> gene mapping to the commonly deleted region in 5q− syndrome patients

18 Jun 2007

Abstract excerpt

Myelodysplastic syndromes (MDSs) are a group of hematopoietic stem cell disorders characterized by ineffective hematopoiesis and peripheral blood cytopenias. Lenalidomide has dramatic therapeutic effects in patients with low-risk MDS and a chromosome 5q31 deletion, resulting in complete cytogenetic remission in >60% of patients. The molecular basis of this remarkable drug response is unknown. To gain insight into...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Lymphocytic Leukemia Research
Share to Erythrocyte Function and Pathophysiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17576924
DOI: 10.1073/pnas.0610477104

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lenalidomide inhibits the malignant clone and up-regulates the <i>SPARC</i> gene mapping to the commonly deleted region in 5q− syndrome patientsPMID 17576924Read ↗

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromesSemantic proximity Read ↗

Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.Semantic proximity Read ↗

Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid MalignanciesSemantic proximity Read ↗

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.Semantic proximity Read ↗

Single cell profiling of del(5q) MDS unveils its transcriptional landscape and the impact of lenalidomideSemantic proximity Read ↗

Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II studySemantic proximity Read ↗

Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome.Semantic proximity Read ↗

PP2A: The Achilles Heal in MDS with 5q DeletionSemantic proximity Read ↗

Clinical Management of Myelodysplastic Syndromes With Interstitial Deletion of Chromosome 5qSemantic proximity Read ↗

A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discoverySemantic proximity Read ↗

Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.Semantic proximity Read ↗

Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.